Trial: 201311112

ANHL12P1- A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN25, NSC# 749710), or Crizotinib (NSC# 749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117

Phase

II

Principal Investigator

Hayashi, Robert

Disease Site

Lymphoid Leukemia; Non-Hodgkin’s Lymphoma; Pediatric Cancers

Learn more about this study at: clinicaltrials.gov